Select patients for cell therapy by whether their tumour holds reactive T cells
Growing a patient's own tumour-fighting cells only works if those cells are there to start with. A test for them would spare futile treatment.
Tumour-infiltrating lymphocyte therapy is approved in melanoma but works in a minority, and manufacturing takes weeks and costs a great deal. Markers of genuinely tumour-reactive T cells, notably CD39 and CD69 co-expression and CXCL13 expression, distinguish reactive from bystander cells in human tumours. A pre-manufacture biopsy assay could predict product potency and patient benefit.
- No one can predict who responds to immunotherapy · Checkpoint drugs cure some patients and do nothing for most. We still cannot tell the two apart before treating.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- Key paperRohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma
Shares Ton Schumacher, John Haanen, Lifileucel, Tumour-infiltrating lymphocytes (TILs).
- IdeaUse patient organoids to check a cell therapy will work before infusing it
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Manufacturing cost and time for living and radioactive medicines.
- TrialC-144-01
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Melanoma.
- Key paperC-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed
Shares Iovance Biotherapeutics, Lifileucel, Tumour-infiltrating lymphocytes (TILs), TIL therapy.
- IdeaStandards for spatial and multiplex tissue biomarkers before they reach the clinic
Shares Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, No one can predict who responds to immunotherapy, Biomarkers are not validated or standardised.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, TIL therapy, Melanoma.
- IdeaGrow immune command posts inside tumours
Shares Tumour-infiltrating lymphocytes (TILs), Single-cell & spatial profiling, No one can predict who responds to immunotherapy, Melanoma.
- InstitutionLeiden University Medical Center
Shares Ton Schumacher, John Haanen, Melanoma.